Please ensure Javascript is enabled for purposes of website accessibility

Why Agenus Stock Is Jumping Today

By Keith Speights - Jun 8, 2021 at 11:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was some positive news, but it probably wasn't a huge catalyst for the stock.

What happened

Shares of Agenus (AGEN -6.38%) were jumping 8.2% as of 11:24 a.m. EDT on Tuesday. The only news related to the company was VBI Vaccines' (VBIV -5.38%) announcement that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for cancer vaccine candidate VBI-1901 in treating recurrent glioblastoma, an aggressive type of brain cancer. VBI's experimental vaccine uses GlaxoSmithKline's AS01 adjuvant system, which contains Agenus' QS-21 Stimulon adjuvant.

So what

VBI stock rose a little with the FDA's decision to give Fast Track designation to VBI-1901. The designation could lead to a shorter path to potential approval of the experimental drug. 

Person wearing a coat and tie holding yellow blocks with red letters spelling FDA.

Image source: Getty Images.

Why would Agenus deliver an even bigger gain than VBI? After all, Agenus stands to benefit less than VBI might from the FDA's move. The most likely answer is that the surge in Agenus' share price really didn't stem primarily from the good news for VBI-1901.

Instead, today's jump for Agenus probably just reflects run-of-the-mill volatility. Agenus didn't have any other news that would serve as a catalyst. It's not unusual for clinical-stage biotech stocks to experience big price swings for no apparent reason.

Now what

The main thing to watch with Agenus now is the FDA's decision on accelerated approval of balstilimab in treating cervical cancer. VBI Vaccines also expects an FDA approval decision on its hepatitis B vaccine candidate later this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends GlaxoSmithKline. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
$2.79 (-6.38%) $0.19
GSK Stock Quote
$34.70 (-1.59%) $0.56
VBI Vaccines Inc. Stock Quote
VBI Vaccines Inc.
$1.23 (-5.38%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.